« Previous
Next »
Titles
- CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments1
- Competitive bidding in drug procurement: evidence from China1
- Equilibrium effects of pharmaceutical bundling: evidence from India1
- Fact sheet. The 340B Drug Pricing Program1
- Manufacturers may need additional guidance to ensure consistent calculations of average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2020 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2021 average sales prices1
- Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters1
- Prescription drugs: spending, use, and prices1
- Report on the affordability of insulin1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1
- State biosimilar substitution laws could reduce consumer access and savings1
- Technical assistance brief: implementation of inflation-indexed rebates for Part B drugs1